Agilent Technologies Inc.

Most Recent

  • uploads///pershing
    Fund Managers

    Ackman’s Pershing Square Increased Agilent Stake in Q3

    This week, Pershing Square disclosed that it had increased its stake in Agilent Technologies (A) to 2.9 million shares in the third quarter.

    By Rabindra Samanta
  • uploads///Graph
    Earnings Report

    How Agilent’s Instruments and Consumables Did in Fiscal 2019

    Agilent Technologies (A) expects its ACG (Agilent CrossLab Group) and DGG (Diagnostics and Genomics Group) revenue momentum to be similar in the first and second halves of fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Agilent Technologies Reduces Its Cash Flow Guidance

    Agilent Technologies (A) has reduced its CFO (cash flow from operations) guidance from $1,100 million–$1,150 million to $1.025 million–$1,075 million.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What’s Expected for Agilent’s Fiscal 2019 EPS

    Agilent Technologies (A) has reiterated its fiscal 2019 non-GAAP EPS guidance of $3.03–$3.07, which represents a rise of 8.6%–10.0% YoY (year-over-year) on a reported basis and 10.0%–11.0% YoY on a CC (constant-currency) basis.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Agilent Technologies Reduces Its Fiscal 2019 Revenue Guidance

    In its second-quarter investor presentation, Agilent Technologies (A) reduced its fiscal 2019 revenue guidance from 5.15 billion–$5.19 billion to $5.085 billion–$5.125 billion, implying 4.0%–4.8% YoY (year-over-year) core revenue growth instead of 5.0%–5.5%.

    By Margaret Patrick
  • uploads///laboratory _
    Earnings Report

    What Analysts Recommend for Agilent Technologies

    On May 14, Agilent Technologies (A) reported its second-quarter results. Its revenue rose 2.65% YoY (year-over-year) on a reported basis to $1.24 billion, missing analysts’ estimate by $30.82 million.

    By Margaret Patrick
  • uploads///RMD ana reco
    Company & Industry Overviews

    What ResMed’s Valuation Trend Indicates

    The mean rating for ResMed (RMD) stock is 2.6, and its target price is $104.69.

    By Kenneth Smith
  • uploads///A ana reco
    Company & Industry Overviews

    What’s the Upside Potential for Agilent Technologies Stock?

    In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.

    By Kenneth Smith
  • uploads///A
    Company & Industry Overviews

    What’s Driving Agilent Technologies’ Segment Growth?

    Agilent Technologies’ (A) Life Sciences and Applied Markets segment had revenues of $510 million in Q3 2017 compared to $540 million in Q3 2018.

    By Kenneth Smith
  • uploads///A SGA
    Company & Industry Overviews

    Agilent Technologies’ Operational Performance

    Agilent Technologies (A) incurred selling, general, and administrative expenses of $339 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Agilent Technologies: Its Acquisition Spree in 2018

    Agilent Technologies (A) has been on an acquisition spree in 2018 with major acquisitions made until the third quarter.

    By Kenneth Smith
  • uploads///chemist _
    Company & Industry Overviews

    How Thermo Fisher Scientific’s Valuation Looks in September

    Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.

    By Mike Benson
  • uploads///part  aluminum export
    Basic Materials

    Trump’s Tariffs: More Countries Investigate China

    Fearing an import deflection following the Section 232 tariffs in the United States, several regions are contemplating tariffs on Chinese steel products.

    By Mohit Oberoi, CFA
  • uploads///Diagnostics segment
    Healthcare

    How Is Roche’s Diagnostics Segments Positioned in August?

    Roche’s tissue diagnostics unit generated revenues of 290.0 million Swiss francs in the second quarter, reflecting ~15% YoY growth at CER.

    By Daniel Collins
  • uploads///war _
    Basic Materials

    Metal Stocks Brace for Tough Times as Trade War Intensifies

    Equity markets closed deep in the red yesterday. Looking at the broader-market ETFs, we see that the SPDR S&P 500 ETF (SPY) lost 1.36%, shrinking its year-to-date (or YTD) losses to 2.4%.

    By Mohit Oberoi, CFA
  • uploads///lab management sytem
    Company & Industry Overviews

    TMO’s Advanced Laboratory Management System Could Gain Market Share

    On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How TMO Stock Has Performed Recently

    On March 14, 2018, Thermo Fisher Scientific (TMO) closed at $213.46 per share.

    By Sarah Collins
  • uploads///HPIC SYSTEM
    Company & Industry Overviews

    A Look at TMO’s New High Pressure Ion Chromatography System

    On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of its new high-pressure Ion Chromatography System.

    By Sarah Collins
  • uploads/// capital deployment strategy
    Company & Industry Overviews

    What Investors Should Know about TMO’s Dividends

    On March 14, 2018, Thermo Fisher Scientific (TMO) stock started trading ex-dividend.

    By Sarah Collins
  • uploads///leerink
    Company & Industry Overviews

    Why Leerink Swann Lowered Its 2018 Estimates for TMO Stock

    On December 4, 2017, Leerink Swann reaffirmed its “outperform” rating on Thermo Fisher Scientific (TMO). It decreased its target price on TMO stock from $216.00 per share to $200.00 per share.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Wall Street Analysts’ ‘Buy’ Ratings and Recommendations on TMO Stock

    On December 4, 2017, Leerink Swan reiterated its “overweight” rating on TMO stock. The investment research firm has a 12-month target price of $200.00 per share on the stock.

    By Sarah Collins
  • uploads///digital science capabilities
    Company & Industry Overviews

    Thermo Fisher Scientific’s Deepening Ties with Sema4

    Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.

    By Sarah Collins
  • uploads///GENETIC ANALYSIS GROWTH STRATEGY
    Company & Industry Overviews

    TMO’s Launch of New Research Assay for Cancer

    On December 7, 2017, Thermo Fisher Scientific announced the launch of a new targeted NGS (next-generation sequencing) research panel.

    By Sarah Collins
  • uploads///A
    Healthcare

    Agilent Technologies’ Downward Sloping Dividend Yield Curve

    Agilent Technologies’ net revenue rose 6.0% in the first nine months of 2017, driven by every segment. Income from operations rose 41.0% as total costs didn’t increase much.

    By Amanda Lawrence
  • uploads///life sciences group
    Company & Industry Overviews

    Thermo Fisher Scientific Accelerates Its Semiconductor Sequencing

    On June 29, 2017, Thermo Fisher Scientific (TMO) announced the addition of three new products to its semiconductor failure analysis workflows portfolio.

    By Sarah Collins
  • uploads///innovation
    Company & Industry Overviews

    Understanding Thermo Fisher’s Growth Strategy

    Thermo Fisher Scientific (TMO) has always focused on innovation as a key growth strategy.

    By Sarah Collins
  • uploads///tho pm
    Basic Materials

    Northcoast Research Upgrades Thor Industries to a ‘Buy’

    Thor Industries (THO) has a market cap of $4.3 billion. It rose 0.06% to close at $77.21 per share on September 13, 2016.

    By Gabriel Kane
  • uploads///VALUATION
    Company & Industry Overviews

    What’s Thermo Fisher Scientific’s Latest Valuation?

    After the release of its 2Q16 earnings results on July 28, 2016, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) multiple of 17.9x–18.5x.

    By Sarah Collins
  • uploads///reveneus
    Company & Industry Overviews

    Thermo Fisher Scientific’s Key Growth Strategy

    Thermo Fisher Scientific reported ~$4.5 billion in revenues in 2Q16, representing YoY (year-over-year) growth of ~6%.

    By Sarah Collins
  • uploads///revenues
    Earnings Report

    Thermo Fisher Scientific’s 2Q16 Revenues: What’s in Store?

    Acquisitions are expected to have a positive impact of approximately 2% on Thermo Fisher Scientific’s 2016 revenues.

    By Sarah Collins
  • uploads///growh catalysts
    Company & Industry Overviews

    What Are Thermo Fisher’s Major Growth Catalysts in 2016?

    Thermo Fisher operates in a market worth $100 billion, with annual growth in the range of 3%–5%. It has a leading market position and expects to grow fast.

    By Sarah Collins
  • uploads///innovation
    Company & Industry Overviews

    How Innovation Is Driving Thermo Fisher Scientific’s Growth

    Thermo Fisher Scientific now has more than 800,000 products in its portfolio and has an extensive product pipeline.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    Understanding Thermo Fisher Scientific’s Valuation among Peers

    On July 08, 2016, Thermo Fisher Scientific was trading at a forward PE (price-to-earnings) multiple of ~18.3x, as compared to the industry average of ~21x.

    By Sarah Collins
  • uploads///affymetric
    Company & Industry Overviews

    Inside Thermo Fisher’s Affymetrix Acquisition: A Growth Gauge

    On January 8, 2016, Thermo Fisher Scientific (TMO) announced the acquisition of Affymetrix for approximately $1.3 billion.

    By Sarah Collins
  • uploads///Hulu streaming service pricing
    Company & Industry Overviews

    DISH’s Sling TV Sees Over-the-Top Success

    The increase in Sling TV subscribers had an adverse effect on DISH’s pay-TV ARPU because Sling TV subscribers pay less than traditional pay-TV subscribers.

    By Shirley Pelts
  • uploads///valuation
    Company & Industry Overviews

    Thermo Fisher Scientific: What’s Been Driving Growth?

    In this series, we discuss the major drivers of Thermo Fisher Scientific’s valuation, stock performance. and growth fundamentals.

    By Sarah Collins
  • uploads///Avg ticket price ticketfly
    Earnings Report

    What Is the Outlook for Pandora?

    Pandora Media (P) had total listener hours of 5.4 billion in 4Q15, a 3% increase over 4Q14.

    By Shirley Pelts
  • uploads///cabedaeaeccfecb
    Company & Industry Overviews

    Why Did Pandora’s Stock Price Rise 8.5%?

    Pandora’s share price has fallen by 40.3% year-to-date. However, the company’s stock price was up by 8.5% on the day the earnings were announced.

    By Shirley Pelts
  • uploads///Tel Gigabit Pro
    Earnings Report

    Will Charter Communications Deploy DOCSIS 3.1 Technology?

    Charter saw revenues of $781 million in its Internet business in 4Q15, a growth of 16.6% YoY, fueled by net customer additions and “price adjustments.”

    By Shirley Pelts
  • uploads///Revs distri for DIS in FY
    Earnings Report

    Disney’s Business Segments: Expectations for Fiscal 2016

    Disney’s Media Networks segment was the biggest contributor to its revenue at 44% with segment revenues of $23.3 billion in fiscal 2015.

    By Shirley Pelts
  • uploads///dcceddfbbebfbbefd
    Earnings Report

    Disney to Continue Share Repurchase Program and Increase Capex

    Disney (DIS) is expected to announce its fiscal 1Q16 earnings on February 9, 2016. Disney is expected to have EPS of $1.44 and revenues of $14.7 billion.

    By Shirley Pelts
  • uploads///NFLX Sandvine
    Company & Industry Overviews

    Netflix Continues Ramping Up Its Original Programming in 2016

    Netflix stated in its 4Q15 letter to shareholders that it intends to launch 600 hours of original programming in 2016.

    By Shirley Pelts
  • uploads///valuation
    Earnings Report

    Thermo Fisher Scientific Trades at Stable Valuation Multiples

    After the release of its 3Q15 earnings results on October 21, 2015, Thermo Fisher Scientific (TMO) traded at PE multiples in the range of 16.7x–17.0x.

    By Sarah Collins
  • uploads///specialty diagnostics growth drivers
    Earnings Report

    Thermo Fisher: Analytics Instruments and Specialty Diagnostics

    Thermo Fisher Scientfic (TMO) is expected to witness growth in revenues as well as earnings across all segments of the company in 4Q15 as well as 1Q16.

    By Sarah Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    Analyst Recommendations for Thermo Fisher Scientific

    Based on recommendations by 21 broker firms surveyed by Bloomberg, the consensus rating for Thermo Fisher Scientific was “buy” from 19 of the firms and “hold” from two of the firms.

    By Sarah Collins
  • uploads///analytical instruments segmentation
    Company & Industry Overviews

    Thermo Fisher Scientific’s Analytical Instruments Business Segment

    Thermo Fisher Scientific’s Analytical Instruments segment earned revenues of ~$3.3 billion in 2014, representing organic growth of around 4%.

    By Sarah Collins
  • uploads///life sciences solutions
    Company & Industry Overviews

    The Life Sciences Solutions Segment of Thermo Fisher Scientific

    Thermo Fisher Scientific’s Life Sciences Solutions segment earned revenues of ~$4.2 billion in 2014, representing organic growth of around 4%.

    By Sarah Collins
  • uploads///segmentation
    Company & Industry Overviews

    An Overview of Thermo Fisher Scientific’s Business Model

    Thermo Fisher Scientific (TMO) has made a number of acquisitions over the years, resulting in the expansion of the company’s product portfolio with the inclusion of a number of premium brands.

    By Sarah Collins
  • uploads///revenue
    Company & Industry Overviews

    Thermo Fisher Scientific: A Leading Medical Technology Company

    Thermo Fisher Scientific (TMO) is one of the leading medical technology companies in the world, providing a broad portfolio of laboratory equipment and services.

    By Sarah Collins
  • uploads///
    Fund Managers

    Is Teradyne fairly valued relative to its peers?

    Presently, ten analysts have given Teradyne a buy rating, and four have issued a neutral rating, for a consensus target price of $22.17.

    By Santiago Solari
  • uploads///
    Fund Managers

    Teradyne’s momentum may translate to strong full-year results

    Teradyne is set to have 15% year-over-year growth in sales to $1.6 billion in 2014. This growth is driven by share gains in the SoC and memory test markets.

    By Santiago Solari
  • uploads///
    Fund Managers

    Teradyne boasts encouraging market share gains

    Teradyne has about 26% share of the $470-million memory testing market. The company expects to gain 3 to 5 points of share this year.

    By Santiago Solari
  • uploads///
    Fund Managers

    A key analysis of Teradyne’s revenues and earnings

    In 2013, Teradyne survived a weak demand climate for the app processor market. The company’s revenues recovered due to strong SoC product volume growth.

    By Santiago Solari
  • uploads///
    Fund Managers

    Glenview Capital raises its stake in Teradyne

    Glenview Capital Management increased its stake in Teradyne (TER) by 4 million shares from its 3Q14 position to nearly 12 million shares.

    By Santiago Solari
  • uploads///MTW
    Industrials

    Relational Investors goes activist on Manitowoc

    Relational Investors LLC was co-founded by Ralph Whitworth and David Batchelder. It filed a 13D with the SEC last week and said it acquired 11.5 million shares, or an 8.52% stake, in Manitowoc (MTW)

    By Samantha Nielson
  • uploads///Fed Unemployment Forecast
    Financials

    Federal Reserve significantly lowers unemployment forecast

    The Federal Reserve includes formal economic forecasts in the minutes from its Federal Open Market Committee (FOMC) Meetings The Federal Reserve typically releases a short press release after its two day FOMC meeting, with a general overview and its decision on interest rates. A month later, they release the actual minutes of the meeting which […]

    By Brent Nyitray, CFA, MBA
  • uploads///Sovereign Yields
    Financials

    Is it something Bernanke said? Or something else?

    Sovereign yields have been rising since the beginning of May Investors in the U.S. have been focused on the rising yield of the 10-year bond since the beginning of May. Since bottoming out at 1.63% on May 1st, the U.S. 10-year yield has been rising in a dramatic fashion, to close at 2.17% as of […]

    By Brent Nyitray, CFA, MBA
  • uploads///MFA Financial
    Financials

    MFA Financial portfolio yield continues to drop

    MFA Financial is a REIT that invests in both agency and non-agency mortgage backed securities MFA Financial (MFA) is a mortgage Real Estate Investment Trust (REIT) that invests in both agency (government guaranteed) and non-agency (non-guaranteed) mortgage backed securities. Their portfolio is primarily invested in hybrids, adjustable rate mortgages (ARM), and 15 year fixed rate […]

    By Brent Nyitray, CFA, MBA
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.